Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epiestriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | STS | P08842 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL12180048 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL14373308 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL4896486 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL7004654 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223196 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL13123063 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL23743979 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223226 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL8941750 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL2001122 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177565-A1 | METHODS AND MATERIALS FOR INHIBITING/PREVENTING THE TRAFFICKING OF MONOCYTES TO THE CENTRAL NERVOUS SYSTEM | DARTMOUTH COLLEGE (US) | 2025-06-05 | — | — | US | claimed |
| CN-118831098-A | Climbing sand worm effective part extract with diuretic effect and application thereof | 西南民族大学 | 2024-10-25 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023173054-A1 | METHODS AND MATERIALS FOR INHIBITING/PREVENTING THE TRAFFICKING OF MONOCYTES TO THE CENTRAL NERVOUS SYSTEM | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20190180877-A1 | ESTROGEN METABOLITE LEVELS AND CYP1B1 POLYMORPHISMS IN LUNG CANCER DIAGNOSIS, PROGNOSIS, AND RISK ASSESSMENT | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2019-06-13 | — | — | US | claimed |
| US-20040102427-A1 | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease | DIMERA, INCORPORATED | 2004-05-27 | — | — | US | claimed |
| WO-2004032897-A2 | PHARMACEUTICAL PREPARATIONS, USE OF SAID PREPARATIONS AND METHOD FOR INCREASING THE BIOAVAILABILITY OF MEDICAMENTS FOR PERORAL ADMINISTRATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-0409176-B1 | Method and materials for detecting pathology from alterations in estrogen metabolism | UNIV ROCKEFELLER (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1996030023-A1 | 19-OXYGENATED STEROIDS AS THERAPEUTIC AGENTS | PETROW VLADIMIR (US) | 1996-10-03 | — | — | WO | claimed |
| US-5438049-A | 16-epiestriol to prevent, inhibit, or reduce inflammation without glycogenic effects | LATMAN NEAL S (US) | 1995-08-01 | — | — | US | claimed |
| EP-0409176-A2 | Method and materials for detecting pathology from alterations in estrogen metabolism | THE ROCKEFELLER UNIVERSITY (US) | 1991-01-23 | — | — | EP | claimed |
| US-4795747-A | 16-epiestriol to prevent, inhibit or reduce inflammation | LATMAN NEAL S (US) | 1989-01-03 | — | — | US | claimed |
| US-4592869-A | Selective acylation process | AKTIEBOLAGET LEO (SE) | 1986-06-03 | — | — | US | claimed |
| EP-0138153-A2 | A selective acylation process | AB LEO (SE) | 1985-04-24 | — | — | EP | claimed |
| US-4321208-A | Preparation of directly iodinated steroid hormones and related compounds | SAHADEVAN VELAYUDHAN | 1982-03-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ESR1 1524/4885ESR2 409/4885LMNA 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.